Results 61 to 70 of about 11,066 (220)

Effects of hallucinogenic drugs on the human heart

Frontiers in Pharmacology
Hallucinogenic drugs are used because they have effects on the central nervous system. Their hallucinogenic effects probably occur via stimulation of serotonin receptors, namely, 5-HT2A-serotonin receptors in the brain.
Joachim Neumann, Stefan Dhein, Uwe Kirchhefer, Britt Hofmann, Ulrich Gergs   +4 more
doaj   +1 more source

A mood disorder episode with an onset under chronic cannabis consumption and accompanied with psychotic features immediately after N, N-Dimethyltryptamine (DMT) use: a case report [PDF]

Düşünen Adam Psikiyatri ve Nörolojik Bilimler Dergisi, 2011
, N-dimethyltryptamine (DMT) is a serotonin agonist hallucinogen, similar to lysergic acid diethylamide (LSD). Syntetic production of DMT as well as extraction from several plants of South American flora is possible.
Güliz Özgen, İlker Küçükparlak, Gökhan Umut, Ahmet Türkcan   +3 more
doaj  

Therapeutic Use of LSD in Psychiatry: A Systematic Review of Randomized-Controlled Clinical Trials

Frontiers in Psychiatry, 2020
Lysergic acid diethylamide (LSD) was studied from the 1950s to the 1970s to evaluate behavioral and personality changes, as well as remission of psychiatric symptoms in various disorders.
Juan José Fuentes, Francina Fonseca, Francina Fonseca, Francina Fonseca, Matilde Elices, Matilde Elices, Magí Farré, Magí Farré, Marta Torrens, Marta Torrens, Marta Torrens   +10 more
doaj   +1 more source

Safety pharmacology of acute mescaline administration in healthy participants

British Journal of Clinical Pharmacology, EarlyView.
Aims Psychedelics, including mescaline, may serve as novel treatments for depression and anxiety. However, data is scarce on the safety of mescaline. Methods The present pooled analysis included two double‐blind, randomized, placebo‐controlled studies with a total of 48 participants and 96 mescaline administrations. Single oral‐dose administrations (n =
Aaron Klaiber, Mélusine Humbert‐Droz, Laura Ley, Yasmin Schmid, Matthias E. Liechti   +4 more
wiley   +1 more source

Preclinical models for evaluating psychedelics in the treatment of major depressive disorder

British Journal of Pharmacology, EarlyView.
Psychedelic drugs have seen a resurgence in interest as a next generation of psychiatric medicines with potential as rapid‐acting antidepressants (RAADs). Despite promising early clinical trials, the mechanisms which underlie the effects of psychedelics are poorly understood.
Laith Alexander, Dasha Anderson, Luke Baxter, Matthew Claydon, James Rucker, Emma S. J. Robinson   +5 more
wiley   +1 more source

Polypharmacy among anabolic-androgenic steroid users: A descriptive metasynthesis [PDF]

, 2015
Background: As far as we are aware, no previous systematic review and synthesis of the qualitative/descriptive literature on polypharmacy in anabolic-androgenic steroid(s) (AAS) users has been published. Method: We systematically reviewed and synthesized
AJ Gruber, AJ Gruber, AJ Gruber, AJ McBride, AJ Viera, Astrid Bjørnebekk, B Hegazy, B Larance, C Ahlgrim, C Wilson-Fearon, Cecilie Schou Andreassen, CN Schäfer, CS Cornford, D Hoff, D Moher, D Moher, D Sagoe, D Sagoe, DA Malone Jr, DL Katz, Dominic Sagoe, E Chahla, E Pappa, F Klötz, G Kanayama, G Kanayama, G Kanayama, G McKillop, GS Goldfield, H Angoorani, H Geyer, HB Moss, HB Moss, HG Pope Jr, HG Pope Jr, IBM Corp, J Bilard, JA Smith, JD Wines, Jim McVeigh, JR Hoffman, K Skårberg, K Skårberg, K Skårberg, KA Clauson, L Degenhardt, L Lundholm, LJ Silvester, M Chandler, M Dunn, M Evans-Brown, Marie-Stella Essilfie, MJ Evans-Brown, N Gårevik, P Korkia, P Korkia, P Lenehan, PJ Fudala, PJ Perry, PJ Perry, R Davies, R Peters, R Shaw, RH Strauss, RP Kusserow, RT Dawson, S Darke, SM Filiault, Ståle Pallesen, T Dodge, T Hildebrandt, TA Pagonis, V Tallon, VD Hope, W Rashid   +74 more
core   +2 more sources

The Australia story: Current status and future challenges for the clinical applications of psychedelics

British Journal of Pharmacology, EarlyView.
Abstract The past decade has seen a huge increase in clinical research with psychedelic drugs and 3,4‐methylenedioxymethamphetamine (MDMA), which have revealed great potential for treating mental health conditions. Given this progress in research, as well as the current unmet clinical need of millions of patients, in 2023, the Australian Therapeutic ...
David J Nutt, Peter Hunt, Anne Katrin Schlag, Paul Fitzgerald   +3 more
wiley   +1 more source

Class A drug abuse: an ophthalmologist's problem? [PDF]

, 2005
[First Paragraph] The 2002/3 British Crime Survey reported that 3% of all 16 to 59 year olds (equating to around one million people) had used a class A drug in the last year.
Firth, A.Y.
core   +1 more source

Psilocybin as a novel treatment for chronic pain

British Journal of Pharmacology, EarlyView.
Abstract Psychedelic drugs are under active consideration for clinical use and have generated significant interest for their potential as anti‐nociceptive treatments for chronic pain, and for addressing conditions like depression, frequently co‐morbid with pain.
Tate Askey, Reena Lasrado, Maria Maiarú, Gary J. Stephens   +3 more
wiley   +1 more source

Acute Effects of Lysergic Acid Diethylamide on Circulating Steroid Levels in Healthy Subjects [PDF]

, 2016
Lysergic acid diethylamide (LSD) is a serotonin 5-hydroxytryptamine-2A (5-HT2A ) receptor agonist that is used recreationally worldwide. Interest in LSD research in humans waned after the 1970s, although the use of LSD in psychiatric research and ...
Armario, Azizi, Bosch, Brown, Connell, Dolder, Dolder, Eisenegger, Evans, Frohman, Fuller, Gasser, Grossman, Hamidovic, Harris, Harris, Hasler, Hoagland, Hollister, Hysek, Hysek, Hysek, Hysek, Hysek, Johnson, Kar, Karssen, Kroboth, Lennartsson, Lu, Mello, Mendelson, Mendelson, Mitra, Murphy, Nadeem, Nichols, Oddie, Odermatt, Oswald, Passie, Rees, Rickli, Sackler, Schmid, Schmid, Schmid, Schmidt, Seibert, Seifritz, Simmler, Simmler, Sofuoglu, Sripada, Ward, Wolkowitz, Yonkers   +56 more
core   +1 more source